These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22177380)

  • 1. Communication of potential benefits and harm to patients and payers in psychiatry: a review and commentary.
    Wu R; Kemp DE; Sajatovic M; Zhao J; Calabrese JR; Gao K
    Clin Ther; 2011 Dec; 33(12):B62-76. PubMed ID: 22177380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs associated with attempted suicide among individuals with bipolar disorder.
    Stensland MD; Zhu B; Ascher-Svanum H; Ball DE
    J Ment Health Policy Econ; 2010 Jun; 13(2):87-92. PubMed ID: 20919595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical relevance of treatments for acute bipolar disorder: balancing therapeutic and adverse effects.
    Srivastava S; Ketter TA
    Clin Ther; 2011 Dec; 33(12):B40-8. PubMed ID: 22177379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for change.
    Martinez-Arán A; Vieta E; Chengappa KN; Gershon S; Mullen J; Paulsson B
    Bipolar Disord; 2008 Jul; 10(5):566-79. PubMed ID: 18657241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinician-patient E-mail communication: challenges for reimbursement.
    Komives EM
    N C Med J; 2005; 66(3):238-40. PubMed ID: 16130953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving mental health treatments through comparative effectiveness research.
    Wang PS; Ulbricht CM; Schoenbaum M
    Health Aff (Millwood); 2009; 28(3):783-91. PubMed ID: 19414887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
    Hoomans T; van der Roer N; Severens JL; Delwel GO
    Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Communicating the benefits and harms of treatments.
    Akobeng AK
    Arch Dis Child; 2008 Aug; 93(8):710-3. PubMed ID: 18456681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effectiveness and cost of a systematic care program for bipolar disorder.
    Simon GE; Ludman EJ; Bauer MS; Unützer J; Operskalski B
    Arch Gen Psychiatry; 2006 May; 63(5):500-8. PubMed ID: 16651507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generic replacement of clozapine: a simple decision model from a Canadian perspective.
    Layton S; Barbeau M
    Curr Med Res Opin; 2004 Apr; 20(4):453-9. PubMed ID: 15119982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding and teaching key concepts and tools of evidence-based medicine: perspectives of a clinician-researcher pharmaceutical physician.
    Karagianis J
    Clin Ther; 2011 Dec; 33(12):B3-10. PubMed ID: 22177378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantifying clinical relevance in treatments for psychiatric disorders.
    Citrome L
    Clin Ther; 2011 Dec; 33(12):B1-2. PubMed ID: 22177375
    [No Abstract]   [Full Text] [Related]  

  • 18. Critical issues on the use of network meta-analysis in psychiatry.
    Yildiz A; Vieta E; Correll CU; Nikodem M; Baldessarini RJ
    Harv Rev Psychiatry; 2014; 22(6):367-72. PubMed ID: 25377612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Likelihood of Being Helped or Harmed as a Measure of Clinical Outcomes in Psychopharmacology.
    Andrade C
    J Clin Psychiatry; 2017 Jan; 78(1):e73-e75. PubMed ID: 28129502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valuation and attainment of treatment goals in schizophrenia: perspectives of patients, relatives, physicians, and payers.
    Kuhnigk O; Slawik L; Meyer J; Naber D; Reimer J
    J Psychiatr Pract; 2012 Sep; 18(5):321-8. PubMed ID: 22995959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.